SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001725160-24-000087
Filing Date
2024-04-11
Accepted
2024-04-11 07:00:55
Documents
13
Period of Report
2024-04-05
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K zntl-20240405.htm   iXBRL 8-K 35112
  Complete submission text file 0001725160-24-000087.txt   163565

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT zntl-20240405.xsd EX-101.SCH 1904
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT zntl-20240405_lab.xml EX-101.LAB 22548
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT zntl-20240405_pre.xml EX-101.PRE 13048
16 EXTRACTED XBRL INSTANCE DOCUMENT zntl-20240405_htm.xml XML 2821
Mailing Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018
Business Address 1359 BROADWAY, SUITE 801 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, Inc. (Filer) CIK: 0001725160 (see all company filings)

IRS No.: 823607803 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39263 | Film No.: 24837104
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)